These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 30594153)
21. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079 [TBL] [Abstract][Full Text] [Related]
22. Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol. Budillon A; Leone A; Passaro E; Silvestro L; Foschini F; Iannelli F; Roca MS; Macchini M; Bruzzese F; Garcia Bermejo ML; Rodriguez Garrote M; Tortora G; Milella M; Reni M; Fuchs C; Hewitt E; Kubiak C; Di Gennaro E; Giannarelli D; Avallone A BMC Cancer; 2024 Sep; 24(1):1167. PubMed ID: 39300376 [TBL] [Abstract][Full Text] [Related]
23. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial. Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634 [TBL] [Abstract][Full Text] [Related]
24. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073 [TBL] [Abstract][Full Text] [Related]
25. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366 [TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696 [TBL] [Abstract][Full Text] [Related]
27. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N Trials; 2015 Dec; 16():575. PubMed ID: 26673577 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. Zhang H; Kellett C; Lambert P; Kim CA Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907 [TBL] [Abstract][Full Text] [Related]
29. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J; Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182 [TBL] [Abstract][Full Text] [Related]
30. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331 [TBL] [Abstract][Full Text] [Related]
31. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Yamaguchi J; Yokoyama Y; Fujii T; Yamada S; Takami H; Kawashima H; Ohno E; Ishikawa T; Maeda O; Ogawa H; Kodera Y; Nagino M; Ebata T Ann Surg; 2022 Jun; 275(6):1043-1049. PubMed ID: 35258510 [TBL] [Abstract][Full Text] [Related]
32. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641 [TBL] [Abstract][Full Text] [Related]
33. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266 [TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial. Uemura K; Kondo N; Sudo T; Sumiyoshi T; Shintakuya R; Okada K; Baba K; Harada T; Murakami Y; Takahashi S J Hepatobiliary Pancreat Sci; 2024 May; 31(5):351-362. PubMed ID: 38156372 [TBL] [Abstract][Full Text] [Related]
35. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545 [TBL] [Abstract][Full Text] [Related]
36. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015). Yamada D; Kobayashi S; Takahashi H; Iwagami Y; Akita H; Asukai K; Shimizu J; Yamada T; Tanemura M; Yokoyama S; Tsujie M; Asaoka T; Takeda Y; Morimoto O; Tomokuni A; Doki Y; Eguchi H Ann Surg Oncol; 2024 Jul; 31(7):4621-4633. PubMed ID: 38546797 [TBL] [Abstract][Full Text] [Related]
37. Selecting chemotherapy for pancreatic cancer: Far away or so close? Shi S; Yu X Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527 [TBL] [Abstract][Full Text] [Related]
38. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. Zhang C; Yang H; Chang C; Li R; Xiong J; Kang D; He D; Liu XJ; Cheng K; Cao D BMJ Open; 2024 Jul; 14(7):e084274. PubMed ID: 39013651 [TBL] [Abstract][Full Text] [Related]
39. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169 [TBL] [Abstract][Full Text] [Related]
40. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Hewitt DB; Nissen N; Hatoum H; Musher B; Seng J; Coveler AL; Al-Rajabi R; Yeo CJ; Leiby B; Banks J; Balducci L; Vaccaro G; LoConte N; George TJ; Brenner W; Elquza E; Vahanian N; Rossi G; Kennedy E; Link C; Lavu H Ann Surg; 2022 Jan; 275(1):45-53. PubMed ID: 33630475 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]